JP2018507243A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507243A5
JP2018507243A5 JP2017546704A JP2017546704A JP2018507243A5 JP 2018507243 A5 JP2018507243 A5 JP 2018507243A5 JP 2017546704 A JP2017546704 A JP 2017546704A JP 2017546704 A JP2017546704 A JP 2017546704A JP 2018507243 A5 JP2018507243 A5 JP 2018507243A5
Authority
JP
Japan
Prior art keywords
tradipitant
pharmaceutical composition
composition according
amount
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546704A
Other languages
English (en)
Japanese (ja)
Other versions
JP6891385B2 (ja
JP2018507243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/021015 external-priority patent/WO2016141341A1/en
Publication of JP2018507243A publication Critical patent/JP2018507243A/ja
Publication of JP2018507243A5 publication Critical patent/JP2018507243A5/ja
Application granted granted Critical
Publication of JP6891385B2 publication Critical patent/JP6891385B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546704A 2015-03-04 2016-03-04 トラジピタントによる治療方法 Active JP6891385B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021012356A Division JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法

Publications (3)

Publication Number Publication Date
JP2018507243A JP2018507243A (ja) 2018-03-15
JP2018507243A5 true JP2018507243A5 (enExample) 2019-04-11
JP6891385B2 JP6891385B2 (ja) 2021-06-18

Family

ID=55629110

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017546704A Active JP6891385B2 (ja) 2015-03-04 2016-03-04 トラジピタントによる治療方法
JP2021012356A Pending JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法
JP2023006082A Pending JP2023052486A (ja) 2015-03-04 2023-01-18 トラジピタントによる治療方法
JP2024062811A Withdrawn JP2024074963A (ja) 2015-03-04 2024-04-09 トラジピタントによる治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021012356A Pending JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法
JP2023006082A Pending JP2023052486A (ja) 2015-03-04 2023-01-18 トラジピタントによる治療方法
JP2024062811A Withdrawn JP2024074963A (ja) 2015-03-04 2024-04-09 トラジピタントによる治療方法

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3730140A1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR102860817B1 (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA2978736C (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
JP7791832B2 (ja) * 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2003091227A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Tachykinin receptor antagonists
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR100848407B1 (ko) 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 {2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1h-[1,2,3]트리아졸-4-일]-피리딘-3-일}-(2-클로로페닐)-메탄온의 신규 결정질 형태
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
US20090264388A1 (en) 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
WO2008079600A1 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2014093907A1 (en) 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
HK1223820A1 (zh) * 2013-06-24 2017-08-11 Menlo Therapeutics Inc. Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
MX378145B (es) 2015-11-30 2025-03-10 Anacor Pharmaceuticals Inc Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) * 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Similar Documents

Publication Publication Date Title
JP2018507243A5 (enExample)
JP2024074963A5 (enExample)
AU2023233141B2 (en) Method of treatment with tradipitant
RU2707089C2 (ru) Комбинированная композиция
JP2010523587A5 (enExample)
JP2019517542A5 (enExample)
JP2013541583A5 (enExample)
JP2006513184A5 (enExample)
JP2021509395A5 (enExample)
RU2007101686A (ru) Комбинированная композиция
Gautam et al. Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebo-controlled trial
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2016505050A5 (enExample)
JPWO2019241442A5 (enExample)
JP2013536837A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2019535830A5 (enExample)
KR20180074707A (ko) 저 용량 경구 디피리다몰 조성물 및 이의 용도
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
JP6420923B1 (ja) 医薬
CN104906501A (zh) 治疗银屑病的中药组分组合物
Post Treatment of cluster headache symptoms using synthetic tryptamine N, N-diallyl-5 methoxytryptamine
JP6878021B2 (ja) トリプタンとアスコルビン酸を含有する医薬組成物
RU2022102184A (ru) Способ лечения с применением традипитанта
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta